Analysis of critical molecules and signaling pathways in osteoarthritis and rheumatoid arthritis

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 603-607

  Xue, Feng ^a   Zhang, Changqing ^b   He, Zhimin ^a   Ding, Liang ^a   Xiao, Haijun ^a  

^a Fengxian Central Hospital   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Osteoarthritis; Rheumatoid arthritis; Signaling pathways

Indexed keywords

ALSTERPAULLONE; COLLAGEN TYPE 2; IMMUNOGLOBULIN A; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PARTHENOLIDE; SOMATOMEDIN C;

ANTIGEN PRESENTATION; ARTICLE; AT RICH SEQUENCE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETIC SCREENING; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; MICROARRAY ANALYSIS; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; COLLAGEN TYPE I; DATABASES, GENETIC; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GRAFT VS HOST DISEASE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOARTHRITIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 84873863868     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1224     Document Type: Article

References (38)

1. Roach HI: The complex pathology of osteoarthritis: even mitochondria are involved. Arthritis Rheum 58: 2217-2218, 2008.
2. Berenbaum F: New horizons and perspectives in the treatment of osteoarthritis. Arthritis Res Ther 10 (Suppl 2): S1, 2008.
3. Dieppe P: Osteoarthritis of the knee in primary care. BMJ 336: 105-106, 2008.
4. Gay S, Gay RE and Koopman WJ: Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann Rheum Dis 52 (Suppl 1): S39-S47, 1993.
5. Kvien TK: Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22: 1-12, 2004.
6. Beasley J: Osteoarthritis and rheumatoid arthritis: conservative therapeutic management. J Hand Ther 25: 163-171, 2012.
7. Scott DL and Symmons DP: The role of specialists in managing established rheumatoid arthritis. Rheumatology (Oxford) 47: 237-238, 2008.
8. Biswas S, Manikandan J and Pushparaj PN: Decoding the differential biomarkers of Rheumatoid arthritis and Osteoarthritis: A functional genomics paradigm to design disease specific therapeutics. Bioinformation 6: 153-157, 2011.
9. Ungethuem U, Haeupl T, Witt H, et al: Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis. Physiol Genomics 42A: 267-282, 2010.
10. Irizarry RA, Hobbs B, Collin F, et al: Exploration, normalization and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264, 2003.
11. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: 3, 2004.
12. Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57: 289-300, 1995.
13. Huang DW, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
14. Huang da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13, 2009.
15. Lamb J, Crawford ED, Peck D, et al: The connectivity map: using gene-expression signatures to connect small molecules, genes and disease. Science 313: 1929-1935, 2006.
16. Sondergaard BC, Schultz N, Madsen SH, Bay-Jensen AC, Kassem M and Karsdal MA: MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation-divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthritis Cartilage 18: 279-288, 2010.
17. Lawrence MC, Jivan A, Shao C, et al: The roles of MAPKs in disease. Cell Res 18: 436-442, 2008.
18. Kotovuori A, Pessa-Morikawa T, Kotovuori P, Nortamo P and Gahmberg CG: ICAM-2 and a peptide from its binding domain are efficient activators of leukocyte adhesion and integrin affinity. J Immunol 162: 6613-6620, 1999.
19. Kaplan R, Morse B, Huebner K, et al: Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine- phosphatases expressed in brain. Proc Natl Acad Sci U S A 87: 7000-7004, 1990.
20. Wang A and Dennis EA: Mammalian lysophospholipases. Biochim Biophys Acta 1439: 1-16, 1999.
21. Peyrard M, Fransson I, Xie YG, et al: Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene. Hum Mol Genet 3: 1393-1399, 1994.
22. Ferrara JL, Levine JE, Reddy P and Holler E: Graft-versus-host disease. Lancet 373: 1550-1561, 2009.
23. Weetman AP and McGregor AM: Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 15: 788-830, 1994.
24. López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, et al: Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 26: 1864-1870, 2006.
25. Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA and Xu J: Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. J Bone Miner Res 19: 1905-1916, 2004.
26. Guzman ML, Rossi RM, Karnischky L, et al: The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105: 4163-4169, 2005.
27. Miglietta A, Bozzo F, Gabriel L and Bocca C: Microtubule-interfering activity of parthenolide. Chem Biol Interact 149: 165-173, 2004.
28. Feltenstein MW, Schuhly W, Warnick JE, Fischer NH and Sufka KJ: Anti-inflammatory and anti-hyperalgesic effects of sesquiterpene lactones from Magnolia and Bear's foot. Pharmacol Biochem Behav 79: 299-302, 2004.
29. Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, et al: Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 49: 176-182, 2005.
30. Leost M, Schultz C, Link A, et al: Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem 267: 5983-5994, 2000.
31. Lahusen T, De Siervi A, Kunick C and Senderowicz AM: Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential. Mol Carcinog 36: 183-194, 2003.
32. Hoppener JW, de Pagter-Holthuizen P, Geurts van Kessel AH, et al: The human gene encoding insulin-like growth factor I is located on chromosome 12. Hum Genet 69: 157-160, 1985.
33. Jansen M, van Schaik FM, Ricker AT, et al: Sequence of cDNA encoding human insulin-like growth factor I precursor. Nature 306: 609-611, 1983.
34. Studer RK: Nitric oxide decreases IGF-1 receptor function in vitro; glutathione depletion enhances this effect in vivo. Osteoarthritis Cartilage 12: 863-869, 2004.
35. Retief E, Parker MI and Retief AE: Regional chromosome mapping of human collagen genes alpha 2(I) and alpha 1(I) (COLIA2 and COLIA1). Hum Genet 69: 304-308, 1985.
36. Wenstrup RJ, Cohn DH, Cohen T and Byers PH: Arginine for glycine substitution in the triple-helical domain of the products of one alpha 2(I) collagen allele (COL1A2) produces the osteogenesis imperfecta type IV phenotype. J Biol Chem 263: 7734-7740, 1988.
37. Kikuno R, Nagase T, Ishikawa K, et al: Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 6: 197-205, 1999.
38. Fitz Patrick DR, Carr IM, McLaren L, et al: Identification of SATB2 as the cleft palate gene on 2q32-q33. Hum Mol Genet 12: 2491-2501, 2003.